Navigation Links
Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
Date:3/9/2009

TUSTIN, Calif., March 9 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Cowen and Company 29th Annual Health Care Conference on Wednesday, March 18, 2009 at 9:30 am EDT at the Boston Marriott Copley Place.

A live webcast and archived replay of the company's presentation will be available at the Investor Relations section of Peregrine's website at www.peregrineinc.com. The archived replay will be available for approximately 30 days following the presentation.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                 Media
    info@peregrineinc.com                     Barbara Lindheim
    (800) 987-8256                            (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
2. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
3. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
4. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
5. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
6. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
7. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
8. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
9. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
11. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... September 20, 2014 MediVet America ... perform a groundbreaking surgery at the specialized Wolvega Horse ... superficial digital flexor tendon was ruptured 90% and her ... injury is a death sentence for a horse. , ... stem cell treatments . This revolutionary regenerative option ...
(Date:9/19/2014)... than electricity, to move data would consume much ... growing concern as chips, transistor counts rise. , ... light emitters, modulators, and detectors emitters ... source for optical chips is molybdenum disulfide (MoS2), ... a single, atom-thick layer. Other experimental on-chip light ...
(Date:9/19/2014)... FRANCISCO , Sept. 19, 2014  Nektar ... results from preclinical studies characterizing the analgesic profiles ... peripherally-acting kappa opioid receptor agonist molecules. The preclinical ... polymer medicinal chemistry platform. The analgesic ... in the medical literature. 1,2 Kappa opioid ...
(Date:9/19/2014)... St. Paul, Minnesota (PRWEB) September 19, 2014 ... representatives from related food industries will gather October ... Meeting at the Rhode Island Convention Center in ... exhibition will feature the work of food scientists, ... development, quality control, and food production management. To ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Toward optical chips 2Toward optical chips 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3
... on Wednesday, March 11, 2009 at 4:30 p.m. Eastern ... Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: ... year 2008 financial results, reviewed the Company,s highlights and ... tremendously active year from an execution standpoint as we ...
... SAN FRANCISCO, Calif., March 10 Poniard Pharmaceuticals, Inc. ... on innovative oncology therapies, today announced that it has ... year-end 2008 financial results, which was previously scheduled to ... a.m. Eastern Time, in order to complete its financial ...
... LightSheer(R) Duet(TM) for High Speed Permanent Hair ... Rejuvenation significantly reduce treatment times to provide ... times.SANTA CLARA, Calif., March 10 Lumenis ... of laser, light-based and radio-frequency devices for ...
Cached Biology Technology:OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 2OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 3OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 4OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 5OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 6OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 7OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 8OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 9OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 10OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 11OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 12Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16 2Lumenis(R) Introduces Cost-Saving Innovations at the 2009 American Academy of Dermatology (AAD) Annual Meeting 2Lumenis(R) Introduces Cost-Saving Innovations at the 2009 American Academy of Dermatology (AAD) Annual Meeting 3
(Date:9/19/2014)... plants regulate their symbiotic relationship with soil bacteria ... the plant structure from leaves into the roots ... the roots. This collaborative study was conducted by ... the Graduate University for Advanced Studies (SOKENDAI), and ... Japan. , Legumes, an important plant family ...
(Date:9/18/2014)... research into the Crimean-Congo hemorrhagic fever virus (CCHFV), a ... humans similar to that caused by Ebolavirus, has identified ... has the potential to lead to novel targets for ... research, reported in a paper published today in the ... at the Texas Biomedical Research Institute and their colleagues, ...
(Date:9/18/2014)... season that prompts millions of Americans to undertake jaunts into ... last a little longer within a century, according to new ... some areas of the United States as summer temperatures linger ... journal Global Ecology and Biogeography . For instance, the ... state tree of New Hampshire could change color one ...
Breaking Biology News(10 mins):For legume plants, a new route from shoot to root 2Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4
... June 2008 Elsevier, a world-leading publisher of ... is pleased to announce the publication of Bioscience ... radical hypotheses on topics throughout the life sciences. ... stimulate innovation by choosing work that is interesting ...
... Highlights from the American Chemical Society journal, ACS Nano ... link to the May 2008 edition. In the current ... from solution-cast quantum dots could increase power conversion efficiencies in ... and systematic technique for evaluating the toxicity of nanomaterials in ...
... Scientists, reporting in the current issue of the online ... of epileptic seizures and behavioral abnormalities in California sea ... as a fetus. The findings follow an analysis earlier ... Marine Mammal Center that showed this brain disturbance to ...
Cached Biology News:Elsevier launches Bioscience Hypotheses 2Domoic acid from toxic algal blooms may cause seizures in California sea lions 2
... is involved in translation initiation. PHAS-II is ... bind to eIF-4E, the mRNA cap-binding protein, ... vitro and in cells. Phosphorylation in the ... This allows eIF-4E to bind to eIF-4G ...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
MAb to IgG2 (Fc gamma-2) IgG2 (Fc, gamma-2 epitope)...
Biology Products: